Long-term treatment with Sitagliptin, a dipeptidyl peptidase-4 inhibitor, reduces colon carcinogenesis and reactive oxygen species in 1,2-dimethylhydrazine-induced rats-Reference-Cited by-同舟云学术

Long-term treatment with Sitagliptin, a dipeptidyl peptidase-4 inhibitor, reduces colon carcinogenesis and reactive oxygen species in 1,2-dimethylhydrazine-induced rats

Published:2013-05-29 Issue:10 Volume:133 Page:2498-2503
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Femia Angelo Pietro¹,Raimondi Laura¹,Maglieri Giulia¹,Lodovici Maura¹,Mannucci Edoardo²,Caderni Giovanna¹

Affiliation:

1. Section of Pharmacology and Toxicology; NEUROFARBA Department, University of Florence; Florence; Italy

2. Diabetes Agency; Careggi Teaching Hospital; Florence; Italy

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference25 articles.

1. Possible mechanisms relating diet and risk of colon cancer;Bruce;Cancer Epidemiol Biomarkers Prev,2000

2. Diabetes and cancer: a consensus report;Giovannucci;Diabetes Care,2010

3. Incretin-based therapies for type 2 diabetes mellitus;Lovshin;Nat Rev Endocrinol,2009

4. The “cryptic” mechanism of action of glucagon-like peptide-2;Rowland;Am J Physiol Gastrointest Liver Physiol,2011

5. Glucagon-like peptide-1 (GLP-1) receptor agonists or DPP4 inhibition does not accelerate neoplasia in carcinogen treated mice;Kissow;Regul Pept.,2012

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synergistic Antitumor and Apoptotic Activity of Sitagliptin or Linagliptin Plus Cisplatin Against A549 Lung Cancer Cells (an Invitro Study);Journal of Contemporary Medical Sciences;2024-07-02

2. Repurposing drugs targeting metabolic diseases for cancer therapeutics;Drug Discovery Today;2023-09

3. Diabetes and Cancer;The Diabetes Textbook;2023

4. Crosstalk between incretin hormones, Th17 and Treg cells in inflammatory diseases;Peptides;2022-09

5. Dipeptidyl peptidase 4-inhibitor treatment was associated with a reduced incidence of neoplasm in patients with type 2 diabetes: a meta-analysis of 115 randomized controlled trials with 121961 participants;Expert Opinion on Investigational Drugs;2022-08-22